Verax Biomedical is committed to improving human health through enhancing the safety of the world’s blood supply. Verax’s first products, currently in development, are rapid tests to detect a broad spectrum of bacterial contaminates based upon its proprietary Bacterial Class Detection (BCD) technology. Bacterial contamination in platelets and red blood cells represents the greatest lethal risk in transfusion medicine today. Every year over 17 million patients receive in excess of 60 million units of these blood components, and each of these components is potentially at risk. Yet no methods are presen.haravailable to address the threat posed by bacterial contamination.